Free shipping on all orders over $ 500

Evolocumab

Cat. No. M1595

All AbMole products are for research use only, cannot be used for human consumption.

Evolocumab Structure
Synonym:

AMG 145 ; Repatha

Size Price Availability Quantity
1mg USD 480  USD480 In stock
2mg USD 680  USD680 In stock
5mg USD 1080  USD1080 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Evolocumab binds to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface. PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood. In the absence of PCSK9, there are more LDL receptors on the surface of liver cells to remove LDL-C from the blood. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.

Chemical Information
Molecular Weight 141788.63
Formula C6242H9648N1668O1996S56
CAS Number 1256937-27-5
Storage -80°C for long term
References

[1] Jun Zhang, et al. Proc (Bayl Univ Med Cent). Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia

[2] Marian McDonagh, et al. J Manag Care Spec Pharm. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

[3] Weinreich M, et al. Cardiol Rev. Antihyperlipidemic therapies targeting PCSK9.

Related PCSK9 Products
PCSK9-IN-13 

PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM.

PCSK9 ligand 1 

PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand.

AZD0780

AZD0780 (PCSK9-IN-12, EX-A6975) is an oral, potentially first-in-class small molecule inhibitor of PCSK9. AZD0780 (PCSK9-IN-12, EX-A6975) has bind affinity for PCSK9 with a Kd value of <200 nM. AZD0780 (PCSK9-IN-12, EX-A6975) can be used for the research of cholesterol metabolism.

NNC0385-0434

NNC0385-0434 is a peptide based on the epidermal growth-factor-like domain A of the human LDLR peptide. NNC0385-0434 competitively binds free PCSK9 and subsequently prevents PCSK9 binding to the LDLR. NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies.

CiVi-008

CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism.

  Catalog
Abmole Inhibitor Catalog




Keywords: Evolocumab, AMG 145 ; Repatha supplier, PCSK9, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.